Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Video from may/9/2019
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by Hotshot85on Jul 08, 2021 9:07am
190 Views
Post# 33511075

RE:RE:RE:RE:RE:RE:RE:RE:RE:Video from may/9/2019

RE:RE:RE:RE:RE:RE:RE:RE:RE:Video from may/9/2019the messaging around timelines has gotten better in the last 6-8 months. very non-commital to specific time frames. prior to that however there was a lot of over promise and under deliver. 

I would like the opposite to happen here. have the messaging under promis and then deliver huge on releases.  

i guess the only problem is when they did that last time complete stage 2 analysis, stock fell off a cliff on the great release.  

this is going to be a tough one to be in until partnering or sale. the longer i'm tied up in it, the smaller my YOY average return shrinks when it eventually does sell

thats the balance for me, trying to figure out if my money is better off being in a different company for 6 months....... however we could wake up tomorrow and this could have been sold for $20 per share
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities